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Abstract  
 
Genetic risk for breast cancer is conferred by a combination of multiple variants 
of small effect. To better understand how risk loci might combine, we examined 
whether risk-associated genes share regulatory mechanisms. We created a breast 
cancer gene regulatory network between transcription factors (TFs) and putative 
target genes (regulons) and asked whether specific regulons are enriched for 
genes associated with risk loci via eQTLs. We identified 36 overlapping regulons 
that were enriched and formed a distinct cluster within the network, suggesting 
shared biology. The risk-TFs driving these regulons are frequently mutated in 
cancer and lie in two opposing subgroups, which relate to ER+ luminal A/B and 
to ER- basal-like cancers and to different, luminal epithelial cell populations in 
the adult mammary gland. Our network approach provides a foundation to 
reveal the regulatory circuits governing breast cancer, to identify targets for 
intervention, and is transferable to other disease settings.  
 
Introduction 
 
Polygenic disease susceptibility results in a distribution of risk within the population. 
Given the large number of known risk loci there is a huge number of possible 
combinations of genotypes associated with high risk. Therefore, in parallel with the 
ongoing analysis of individual loci, a framework is needed to understand how 
multiple risk variants can combine at the cellular level, and indicate whether they 
work through many different mechanisms or – which would be more tractable for 
understanding and intervention – whether they converge on just a few. Germline 
variants will interact not only with each other, but with exposures and with acquired 
somatic events. Ideally, the framework should be able to capture these interactions. 
 
Systems biology approaches may be able provide such a framework1. Protein-protein 
interaction networks have been derived in attempts to shed light on the pathways 
underlying risk2, but most of these networks remain sparse and have only yielded 
limited insight into cancer risk. Most germline risk variants are thought to affect gene 
expression. Therefore regulatory networks may be an appropriate starting point to 
understand the combinatorial effect of risk variants.  
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Here, we model breast cancer as such a gene regulatory network3 onto which the loci 
relating to risk can be mapped to identify key regulators4. We extend our previous 
analysis4 to map onto the network all genes that are associated with the known breast 
cancer GWAS loci5. We found that the transcription factors (TFs) regulating the 
genes linked to risk loci cluster within the network, suggesting potential commonality 
of mechanisms. We also show that the same TFs are frequently mutated in breast 
cancer. Our analysis provides insight into the gene regulatory circuits operating in 
breast cancer and has implications for treatment and for the identification of novel 
therapeutic targets. The approach can be applied in any other settings where data from 
GWAS, large-scale genotyping and gene expression are available.  
 
 
Results 
 
Mapping of breast cancer risk loci to regulatory networks 
Briefly, our analysis builds a regulatory network and then asks for each regulon in the 
network whether the genes within it are linked to more risk loci than would be 
expected by chance. In a subsequent step we examine whether the risk regulons, and 
the TFs driving them, cluster in the overall network. 
 
First we created a regulatory network for breast cancer using the ARACNe 
algorithm3,4 which defines regulons (possible target genes) for a set of curated TFs. 
Each TF-regulon is composed of all those genes whose gene expression data display 
significant mutual information with that of a given TF and are therefore likely to be 
regulated by that TF. We previously validated the functional significance of these 
regulons using ChIP-seq data and TF-knock-down studies4. Regulatory networks 
were inferred using separate analyses on gene expression data from the METABRIC 
cohort I (n=997) and II (n=995)6. Within each network regulons overlap because 
many genes are regulated by more than one TF. We confirmed that copy number 
variation does not significantly impact the network structure (Supplementary Note,  
Supplementary Fig. 1).  
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Secondly, we identified regulons enriched for genes associated with risk loci using 
EVSE (eQTL-conditioned variant set enrichment)4. GWAS identify risk loci, marked 
by tagging SNPs that may themselves not be causative. Therefore each tagging SNP 
was expanded into an associated variant set (AVS)7 that includes all SNPs in strong 
linkage disequilibrium (methods). We then used variation in gene expression to 
determine which risk loci can be assigned to a given regulon using eQTL4 (expression 
quantitative trait loci; SNPs where allelic differences determine expression of a target 
gene). We used a multivariate eQTL analysis to test the association between the 
genotypes of the SNPs in each AVS, and, for each regulon separately, the expression 
of all the genes that lay within a +/- 250kb window around the AVS. If such an 
association was found, the locus was counted towards a mapping tally of the number 
of GWAS loci associated with genes in the regulon. Finally the statistical significance 
of the mapping tally was assessed by permutation analysis (methods, Supplementary 
Fig. 2). We refer to TFs whose regulons were significantly enriched as "risk-TFs".  
 
We carried out the EVSE analysis independently for cohort I and II of the 
METABRIC cancer data set and identified 63 and 61 TFs, respectively, with 
significant enrichment scores, but none using the much smaller data set from normal 
tissue (Supplementary Fig. 3). Frequently, a single risk locus contributes to the 
mapping tally of many regulons. This can be driven by a single gene that is part of 
many regulons or by multiple distinct genes encoded at that locus contributing to the 
association with different regulons (Supplementary Note, Supplementary Figure 4).  
The regulons for 36 TFs were significant in both cohorts (Fig. 1a,b).   
 
Validation of the risk-TFs 
To gain confidence in the identification of the 36 risk-TFs, we tested the effects of 
changing the input GWAS data or regulons on the resultant enrichment score. The red 
box plots in Figure 1c show the average enrichment score for the 36 risk-TFs using 
eQTLs and regulons from METABRIC. When replacing the breast cancer GWAS 
data, we found that GWAS hits for bone mineral density (BMD), chronic lymphocytic 
leukaemia (CLL) or random SNPs did not give significant enrichment scores (Fig. 1c 
blue box plots). For prostate cancer GWAS loci the scores obtained were lower but 
still significant, probably reflecting similarities in these two hormone driven cancers8. 
When we replaced the regulons calculated from METABRIC with random regulons 
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of similar size (Fig. 1c, grey box plots) none of the associations were significant. 
These results support the specificity and validity of the EVSE analysis. Our results 
were not confounded by population stratification (Supplementary Note, 
Supplementary Fig. 5). We did not find enrichment when using normal breast samples 
from METABRIC to calculate eQTLs (white box plot). This is possibly surprising, as 
one might expect inherited risk to be expressed in normal tissue. However, eQTL 
discovery is dependent on sample size9 and only 144 normal tissue samples were 
available in this data set.  
 
Comparison of ARACNe/EVSE to other methods 
We compared our analysis to alternative methods for the derivation of the network 
structure and expansion of tagging SNPs into AVSs and obtained very similar results 
(Supplementary Note, Supplementary Figures 6-8). We also compared our EVSE 
algorithm to analyses in which the multivariate eQTL step was replaced by a distance-
based gene selection, or by using ‘pre-defined’ eQTLs10 from the same sample set 
(Supplementary Note, Supplementary Figures 9-12). EVSE identified more risk-TFs 
and showed better reproducibility than the other tested methods. 
 
Risk-TFs are frequently mutated in breast cancers 
To ask whether somatic and germline variation are associated with the same regions 
of the network, we examined the frequency of mutations and/or copy number changes 
affecting TF genes in data from the Cancer Genome Atlas (TCGA)11. Collectively our 
36 risk-TFs have a significantly increased frequency of alterations compared to 
random genes (Fig. 1d; Supplementary Table 1) and are mutated at a similar 
frequency as annotated cancer genes for which mutations have been causally 
implicated in cancer12 . 
 
Confirmation of risk association using ChIP-seq data 
To validate that our risk-TFs are indeed associated with the regulation of GWAS loci 
we examined ChIP-seq data13 that was generated for TF-eGFP fusion proteins, driven 
from endogenous sequences in MCF-7 cells. We used these data in a variant set 
enrichment (VSE) analysis7 to test whether risk-TF binding sites are enriched at risk 
SNPs. Our analysis correlated the position of TF binding sites with risk AVSs. ChIP-
seq data were available for 9 of our 36 risk-TFs and were compared to 9 low-risk TFs 
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chosen from the EVSE analysis. 5 out of the 9 high-risk TFs, but none of the low-risk 
TFs (Fig. 2a,b), yielded a significant enrichment score. The signal in this analysis is 
likely to be relatively low since fusion proteins rather than the native TFs were 
assayed. When we used ChIP-seq data obtained with anti-FOXA1 and anti-ESR1 
antibodies, much higher enrichment scores were obtained (Fig. 2c), corroborating 
previous results7. CEBPB binding was also enriched at breast cancer risk loci (Fig. 
2c). Some of the TFs, such as AR and PPARD, are expressed at very low levels in 
MCF-7 cells. We therefore tested whether AR binding sites were significantly 
enriched for GWAS hits in the cell line MDAMB453, which belongs to the molecular 
apocrine subclass14 and expresses high levels of AR. Figure 2d shows that after AR 
activation, AR targets yield significant enrichment scores in this cell line. 
Collectively, the ChIP-seq experiments strongly support our conclusion that the risk-
TFs play a role in regulating transcription at risk SNPs. 
 
Confirmation of risk association by master regulator analysis 
Estrogen and FGFR2 signalling pathways are known to be associated with breast 
cancer risk. We examined differential gene expression in response to estrogen and 
FGFR2 signalling in three ER+ breast cancer cell lines: MCF-7, T47D and ZR751. 
Using a master regulator analysis (MRA)15 (methods) we identified MRs consistently 
associated with these responses (Supplementary Note, Supplementary Table 2) and 
found a high prevalence of risk-TFs amongst the MRs, providing further support that 
our risk-TFs are indeed functionally related to breast cancer risk. 
 
Clustering of risk-TFs and clues to function 
To examine whether the different risk-TFs converge on common mechanisms, we 
used ARACNe to calculate the breast cancer regulatory network and mapped onto this 
network the p-values for risk-association (shown in orange to red) using METABRIC 
cohort I. The network was visualised by the degree of overlap of regulons (Fig. 3, 
Supplementary Fig. 13). The enriched regulons mostly cluster together, suggesting 
that the risk-TFs share biological function. 
 
To refine the clustering analysis and look for clues to biological function, we 
extended the RTN16 package (methods) to include the direction of association 
between any TF-target gene pair using Pearson correlation. For all pairs of TFs with a 
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target gene in common, the correlation values were used to assess whether the TFs 
regulated shared target gene in the same direction (up or down), or in different 
(opposite) directions (Fig. 4a-c). This analysis was carried out for all TFs in our 
regulatory network, and the correlation heat map was used in unsupervised clustering 
to generate the dendrogram depicted above the matrix (Fig. 4d). The position of the 
36 risk-TFs is highlighted by the black bars below the dendrogram. 
 
Figure 4e shows an enlargement of the analysis for just the 36 risk-TFs. They fall into 
two distinct groups with high correlation within each group: Gene targets shared 
between two TFs in the same group are regulated in the same direction by both TFs, 
whereas gene targets shared between a TF in one group and a TF in the other, are 
regulated in opposite directions, suggesting the existence of two distinct regulatory 
groups of TFs able to oppose the effects of the other. The two groups of TFs are 
highly expressed in ER+ and ER- tumours respectively (Fig. 4f). Bootstrap analysis 
demonstrated that the split into two distinct groups is extremely stable 
(Supplementary Fig. 14). The behaviour of shared gene targets was mirrored in the 
correlation between the expression of the TFs themselves, but with much weaker 
signals (Supplementary Fig. 15a-c). This may reflect the difference between the 
regulatory activity of a TF, influenced by post-translational regulation and the 
presence of interacting factors, and the level of TF expression. 
 
With respect to the intrinsic breast cancer subtypes, group 1 TFs are highly expressed 
in luminal A and B subclasses, while group 2 TFs are highly expressed in basal 
tumours. Her2 and normal-like tumours showed more heterogeneous gene expression 
patterns (Supplementary Fig. 16). Given this distribution, we tested the enrichment of 
each regulon for genes upregulated in ER+ or ER- tumours using MRA (methods). We 
split each regulon into activated and repressed targets and found that group 1 positive 
targets were enriched in the ER+ gene signature, whilst the negative targets were 
enriched in the ER- signature (Fig. 4e, bar above the matrix). Group 2 generated the 
opposite pattern, demonstrating that each group of TFs is associated with gene 
expression changes in both tumour subtypes, but with opposite effects. 
 
Identification of clusters associated with known breast cancer subtypes 
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The dendrogram generated in Figure 4d was used to draw a tree and leaf diagram 
(Fig. 5a) representing the 555 TFs whose regulons in cohort I were of sufficient size 
to be analysed in the EVSE pipeline. Colouring of regulons indicates p-values for risk 
association. While some risk-TFs occur scattered throughout the diagram, two distinct 
clusters emerge: cluster 1 (enlarged in Fig. 5b) corresponds closely to group 1 in the 
previous analysis. These TFs include those important for the FGFR2 and estrogen 
response and also correlate with the TFs highly expressed in luminal A and B 
subtypes. Group 2 TFs are somewhat more dispersed throughout the tree, but there is 
clear clustering around the TFs YBX1, CBFB, NFIB, TRIM29 and SOX10, labelled 
as cluster 2 (Fig. 5c). Another branch in this node contains the risk-TFs CEBPB and 
TBX19. 
 
A literature survey confirmed that TFs in cluster 2 are primarily associated with basal-
like breast cancer. We therefore tested whether a gene signature for basal tumours17 
was linked to cluster 2 using MRA. Of the six consensus MRs for basal-like cancers 
obtained from the METABRIC cohorts (Supplementary Table 3), the two most 
strongly associated TFs map to this cluster (SOX10, TRIM29). PLAGL1 also maps to 
cluster 2, but none of the basal-like cancer MRs fall within cluster 1.  
 
Given the high differential expression of these clusters of TFs in ER+ and ER- 
tumours, we carried out the EVSE analysis separately in ER+ and ER- tumours. Risk-
TFs for ER+ tumours map to both cluster 1 and 2 (Fig. 5 d-e, Supplementary Fig. 17), 
reinforcing our previous observation that both groups of risk-TFs can play a role in 
ER+ and ER- tumours, most likely with opposite effects. Both clusters were also 
marked by a VSE analysis using pre-defined eQTLs for ER+ tumours or using 
different network construction tools (Supplementary Fig. 18, Supplementary Table 4). 
An EVSE analysis with ER- tumours found very few, non-reproducible risk-TFs (not 
shown). 
 
Activity of cluster 1 and 2 TFs in primary cells 
Next we examined the expression patterns of our risk-TFs in primary cell populations 
isolated from the normal human mammary gland. Gene expression patterns for three 
luminal cell populations have previously been described18: an EpCAM+ CD49f- 
population highly enriched in ER+ cells that express high levels of luminal cell 
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differentiation markers; ER- EpCAM+ CD49f+ ALDH+ cells that function as alveolar 
precursor cells; and ER- EpCAM+ CD49f+ ALDH- luminal cells that have a phenotype 
intermediate between the EpCAM+ CD49f- and the ER- EpCAM+ CD49f+ ALDH+ 
subpopulations. Figure 5f lists the risk-TFs that showed differential gene expression 
across these three populations (adj p-value <0.05). Eight cluster 1 TFs were 
overexpressed in the ER+-enriched population while several cluster 2 TFs (Fig. 5f, 
Supplementary Fig. 19a) were overexpressed in ER- EpCAM+ CD49f+ ALDH+ 
alveolar progenitors. The ALDH- population showed an intermediate pattern. 
Myoepithelial and stromal cells showed no clear expression pattern for the clusters 
(Supplementary Fig. 19b). The gene expression patterns seen in the ALDH+ versus 
the ER+-enriched primary cell population are reminiscent of that seen in basal-like 
versus luminal cancers.  
 
Functional analysis of cluster 2 TFs  
We examined the effect of siRNA knock-down of cluster 2 risk-TFs (NFIB, YBX1, 
CBFB and TBX19) in the ER- (MCF10A) and ER+ (ZR751) cell lines. In MCF10A 
cells, siRNA-targeting of YBX1 strongly reduced proliferation (Fig. 6a), and targeting 
CBFB, NFIB, TBX19 and LMO4 (Fig. 6a, Supplementary Fig. 20) all had a 
significant anti-proliferative effect. In contrast, repression of the cluster 2 TFs in 
ZR751 cells had either no or little effect on proliferation, whilst repression of FOXA1 
strongly inhibited growth (Fig. 6b). Interestingly in ZR751 cells siNFIB led to a 
slight, but significant increase in proliferation, in keeping with the hypothesis that 
members of the two clusters have opposing effects.  
 
Whilst a group of ESR1-cooperating factors was already well defined, our analysis 
has extended the ESR1-cluster and revealed a group of TFs opposing ESR1 function, 
likely to be important in regulating basal-like cancers and their precursors. 
 
Regulon activity as prognostic read-out 
The ESR1 regulon consists of estrogen-induced and estrogen-repressed genes in 
approximately equal proportions.4 Our current analysis suggests that the relative 
activity of these two groups of genes may be important for determining the phenotype 
of the cell. We therefore devised a 2-tailed GSEA (Fig. 7a,b; methods) in which 
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positive and negative targets of the ESR1 regulon are considered separately to 
generate a differential enrichment score (dES) (methods) representing the activity of 
the regulon. We used this in a stratified survival analysis in the METABRIC data 
(Fig. 7c,d). We found a continuous spectrum of dES across the tumors, except near 
the transition between the active and repressed state of the ESR1 regulon, which was 
characterized by an abrupt change. There was a strong trend for better survival with a 
high dES. Interestingly, we identified a set of patients with histochemically ER+ 
tumours that had a repressed ESR1 regulon and a significantly worse outcome than 
those with tumours with an active ESR1 regulon (Fig. 7e,f, Supplementary Fig. 21). 
This is not apparent when stratifying by ESR1 gene expression alone (Supplementary 
Fig. 22). We also tested the effect of tamoxifen treatment on the activity of the ESR1 
regulon in MCF-7 cells using 2-tailed GSEA. As expected, we found that estrogen 
induction of steroid-starved MCF-7 cells led to a strong activation of the ESR1 
regulon (Fig. 7g). However with estrogen plus tamoxifen treatment, the ESR1 regulon 
was shifted towards a more repressed state than with estrogen alone (Fig. 7h). This 
finding suggests that tamoxifen, while inhibiting proliferation, may also push luminal 
tumours to a more basal-like state19.  
 
 
Discussion 
 
Our goal was to develop a network-based approach to understand how the effects of 
multiple GWAS loci combine to influence susceptibility. We derived a TF-centric 
regulatory network for breast cancer and asked by eQTL analysis which regulons 
were enriched for an association with confirmed breast cancer GWAS loci. We 
identified 36 regulons that were enriched in both of two separate analyses. The TFs 
controlling these regulons are frequently mutated in breast cancer, implying a 
convergence of germline and somatic events in the etiology of breast cancer. Many of 
the risk-TFs are master regulators of pathways associated with breast cancer risk, such 
as estrogen and FGFR2 signalling. Within the regulatory network, almost all of the 
risk-TFs clustered around a group of TFs already known to be central to breast cancer 
risk: ESR1, FOXA1, GATA3 and SPDEF4,7. This clustering supports the functional 
significance of the newly identified risk-TFs and suggests that risk-TFs share 
regulatory mechanisms.  
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The validity of the ARACNe/EVSE analysis was confirmed through extensive 
comparisons to other methods. The 36 identified risk-TFs were specific for hormone-
driven cancer and could be validated experimentally. The EVSE analysis avoids the 
multiple testing problems of unrestrained eQTL calling and was therefore able to 
identify more risk-TFs than other methods. However, as in other analyses10, we 
identified eQTLs for only a minority of GWAS loci. Our method utilised gene 
expression data from breast tumours. Yet, our hypothesis is that inherited variation 
exerts its effects on normal tissue, and indeed on specific cell types within that tissue. 
To detect this, improved, context-specific methods for eQTL identification20,21 are 
required. The EVSE analysis we have developed can provide a general approach to 
interpret GWAS data in the context of regulatory networks. 
 
Considering the direction (up or down) of the response of shared target genes revealed 
two distinct clusters of risk-TFs: those in cluster 1 whose positive targets were 
overexpressed in ER+ cancers, and those in cluster 2, whose positive targets were 
overexpressed in basal-like ER- cancers. However, the inverse also holds true: cluster 
2 TFs repress genes associated with ER+ cancers, and cluster 1 TFs repress those 
associated with ER- cancers. Therefore both clusters of TFs are likely to be important 
for the establishment of ER+ and ER- tumours, albeit with opposing effects. This is 
supported by GWAS results, where the majority of loci confer risk for both ER+ and 
ER- disease22. Furthermore, our EVSE analysis using only ER+ tumours identified 
risk-TFs from both clusters.  
 
Some cluster 1 TFs have previously been reported as critical for ER+ disease23-25 
(ESR1, FOXA1, GATA3, SPDEF). We confirmed these and added more validated 
risk-TFs: XBP1, RARA and AR. XBP1 and ESR1 gene expression is highly 
correlated in laser microdissected breast tissue26 and RARA cooperates with ESR1 to 
drive estrogen-induced transcription27. Recent data suggest that in ER- apocrine 
tumours AR is able to replace the function of ESR1, leading to a luminal-like gene 
expression profile28. The identification of XBP1, RARA and AR as risk-TFs fits the 
overall framework that estrogen-driven gene expression is the predominant 
determinant of luminal breast cancer risk.   
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Cluster 2 comprises YBX1, CBFB, NFIB, TRIM29, SOX10, CEBPB and TBX19, all 
highly expressed in ER- tumours. Of these, our functional assays identified YBX1, 
NFIB and CBFB as important for proliferation in ER- cells in culture. Existing 
literature links individual TFs in cluster 2 to basal-like breast cancer29-32, which is 
associated with increased aggressiveness, metastasis and epithelial-to-mesenchymal 
transition (EMT). Here we suggest a network of cooperating TFs important in 
determining this cancer subtype. The link of cluster 2 TFs to basal-like breast cancer 
is further supported by increased binding at GWAS loci by CEBPB, a TF required for 
lobuloalveolar development33 whose loss is associated with EMT34. 
 
The most striking aspect of cluster 1 and 2 TFs is the opposing regulatory effect they 
exert on their target genes. We postulate that this mutually exclusive activity reflects 
the decision of a progenitor to commit to either an ER+ ductal or an ER- alveolar cell 
fate. In line with this hypothesis we find that in primary human mammary cell 
populations18, those representative of ER- alveolar progenitors show differential 
upregulation of cluster 2 TFs, whilst ER+ luminal cells display higher expression of 
cluster 1 TFs (Fig. 8). Recent genetic tracing experiments have shown that the ER+ 
ductal progenitors and ER- alveolar progenitors are self-renewing in the mouse 
mammary gland35,36,37. The differential expression of risk-TFs in these two self-
renewing populations may suggest that these are the populations where risk genes are 
effective and cell transformation occurs. In line with this, transcriptional profiles of 
basal-like tumours most resemble that of ER- alveolar progenitors38,39, while luminal 
A and B tumours phenocopy ER+ ductal cells39-41,18. Furthermore, the ER- alveolar 
progenitor population is expanded in BRCA1 mutation carriers39, which are 
predisposed to develop ER- breast cancer. 
 
The opposing activity of two distinct networks of TFs has not previously been 
reported, but is consistent with studies carried out for individual TFs. For example, 
ELF5, an important inducer of alveolar differentiation42 can reduce estrogen 
sensitivity in ER+ cell lines43. FOXA1 in combination with GATA3 and ESR1 can 
specify an estrogen-responsive phenotype24, and, conversely, is able to repress the 
basal phenotype44. The concept of antagonism between TFs, led us to the 2-tailed 
GSEA analysis of the ESR1 regulon (Fig. 7). Of potential clinical relevance, the 
analysis identifies a subgroup of histochemically ER+ patients in whom the ESR1 
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regulon is functionally in a repressed state and in whom anti-estrogen treatment might 
not be effective. Our results also highlight the possibility that repression of cluster 1 
TFs may lead to a shift in cell state towards more basal-like cancer, that is potentially 
associated with a more aggressive tumour phenotype and resistance to therapy. Better 
understanding of the interplay of the key regulators will be critical for optimal 
therapeutic strategies. 
 
In summary, we have shown that EVSE analysis, together with gene regulatory 
networks, can identify key regulators that may influence disease risk. The analysis 
can be applied to any combination of GWAS loci for which eQTLs can be 
interrogated, not just those for which the causative SNPs and genes are already 
known. For breast cancer, the risk-enriched regulons include many driven by TFs 
already implicated in breast cancer, but many others that were not. The mutual 
antagonism of the two identified clusters of risk-TFs provides novel insights into their 
interactions, with potential clinical implications.  
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Figure legends:  
 
Figure 1: EVSE-based identification of 36 risk-TFs. 
Lists of 36 TF-regulons identified in the EVSE analysis, showing enrichment score 
and p-value based rank order of risk-TFs for METABRIC cohort I (a) and II (b). The 
tagging SNP for each breast cancer GWAS hit5 is listed above the panel, together with 
the number of markers (SNPs in the AVS for which genotypes were available in 
METABRIC) for each locus. The matrix shows each multivariate eQTL test with a 
significant result as a grey box. Mapping tallies are summed on the right of the 
matrix. Box plots show the normalized null distributions of the enrichment scores 
(box: 1st–3rd quartiles; bars: extremes). Solid and open red diamonds highlight 
enrichment scores that satisfy a Bonferroni-corrected threshold for significance of 
P<0.01 and P<0.05, respectively. P-values are based on null distributions from 1,000 
random AVSs. (c) Computational validation of EVSE analysis for cohort I and II. 
Averages of enrichment scores obtained in the EVSE analysis using different GWAS 
data sets (breast cancer (BCa), prostate cancer (PCa), bone mineral density (BMD) or 
chronic lymphocytic leukaemia (CLL) or random SNPs) shown along the x-axis,  
using different regulons and eQTLs (origin indicated by colour). The grey dotted line 
highlights the Bonferroni-corrected threshold (P<0.05). (d) Mean aberration 
frequency of the 36 risk-TFs compared to sets of 36 random genes (empirical 
p<0.001, boxplot whiskers extend to the 99th percentile of the random distribution 
with 10,000 random sets). Aberration frequencies for sets of random TFs and cancer 
genes12 are also shown.  
 
Figure 2: Enrichment of risk-TF binding sites at breast cancer GWAS loci. 
VSE analysis7 of the cistrome of (a) 9 risk-TFs and (b) 9 non-risk TFs defined in the 
EVSE analysis for which ChIP-seq data was available13 in MCF-7 cells. Cells were 
transfected with BAC-fusion proteins (BAC-FP) of the relevant TF and eGFP and 
grown in full medium. Antibodies against eGFP were used in these ChIP experiments. 
VSE tallies that yielded a significant enrichment score are shown in dark grey, those 
that did not in light grey. (c) VSE analysis of ChIP-seq experiments using α-ESR1, α-
FOXA1 and α-CEBPB antisera in MCF-7 cells. Cells were grown in full medium 
(FM). (d) VSE analysis of ChIP-seq data for AR using the molecular apocrine cell 
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line MDAMB453 stimulated as indicated with DHT: 5αdihydro-testosterone; MPA: 
medroxyprogesterone acetate or vehicle treated or grown in full medium. Box plots 
show the normalized null distributions (box: 1st–3rd quartiles; bars: extremes). 
Diamonds show the corresponding VSE scores, either in black or in red for mapping 
tallies that satisfy a Bonferroni-corrected threshold for significance (P<0.01). P-
values are based on null distributions from 1,000 random AVSs. 
  
Figure 3: Regulatory network for breast cancer, showing clustering of breast 
cancer risk.  
The network is depicted on the basis of the overlap of regulons, with risk association 
shown in yellow to red (based on cohort I of METABRIC). The 36 consensus risk-
TFs identified in both cohorts are labelled. The colouring of the edges (shown in light 
green to blue) indicates the overlap as measured by the Jaccard coefficient (JC) and 
the size of circles represents the size of each regulon. Only regulons with JC ≥ 0.4 are 
shown in the diagram. All regulons and a heatmap depicting the overlap of the 
regulons of risk-TFs is shown in Supplementary Figure 13. BCa risk: Bonferroni 
adjusted p-values obtained for each regulon when calculating the enrichment with 
breast cancer GWAS loci in the EVSE analysis, using cohort I for calculating the 
network and eQTLs. P-values are based on null distributions from 1,000 random 
AVSs.  
 
Figure 4: Correlation of expression of targets shared between TF pairs in breast 
tumours.  
(a-c) Correlations of gene expression between a given TF and its targets were plotted 
for three different TF-TF pairs as indicated. Above each panel a cartoon depicts the 
observed interactions. Red circles indicate co-activation, blue circles co-repression. 
Targets are shown in grey if the two TFs have opposing effects on the target. (d) Heat 
map of the correlation of gene expression for targets shared by any pair of the 555 
TFs (cohort I, METABRIC) whose regulons were of sufficient size to be analysed in 
the EVSE pipeline. Unsupervised clustering was applied to this correlation heat map 
resulting in the dendrogram shown at the top of the plot. The black bars depict the 36 
risk-TFs, which fall into two distinct clusters. (e) Enlargement of the correlation heat 
map for the risk-TFs only. Above the matrix a bar with yellow to red colouring 
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depicts the results (BH adjusted p-values) of a MRA analysis for the enrichment 
within each regulon of positive and negative targets that are upregulated in ER+ or 
ER- tumours, respectively, in cohort I of the METABRIC samples. The panel to the 
left of the matrix shows the master regulators identified for the FGFR2 and E2 
responses. (f) Relative gene expression levels of the risk-TFs in ER+ or ER- tumours 
in cohort I of the METABRIC samples: expression levels were averaged in all ER+ 
and all ER- tumours and compared to expression levels averaged across all samples. 
TFs are shown ranked by differential gene expression between ER+ and ER- tumours.  
 
Figure 5: Tree and leaf representation of correlation matrix reveals two clusters 
of risk-TFs. 
(a) Tree and leaf representation of the dendrogram depicted in Figure 4d, where 
branches represent the arms in the dendrogram. The size of regulons is represented by 
circle size as indicated and Bonferroni adjusted p-values for EVSE enrichment of 
regulons for breast cancer GWAS loci in cohort I are shown in colour. Only 
consensus risk-TFs are labelled. (b) Enlargement of cluster 1 and (c) cluster 2 of the 
correlation heat map. All TFs present in these clusters are labelled, independent of 
risk association. (d-e) EVSE analysis showing enrichment score and p-value based 
rank order of the 36 risk-TFs for cohort I (d) and cohort II (e) using only ER+ 
tumours from the METABRIC dataset. The mapping tallies are shown in 
Supplementary Figure 17. (f) Relative gene expression levels of the risk-TFs that are 
differentially expressed in a comparison of three primary human luminal mammary 
cell populations18 as listed (P<0.05; BH adjusted from limma comparisons, see 
methods). Expression (Z-score) in each subpopulation is calculated relative to the 
average in the three populations analysed, and ranked by differential expression 
between the ALDH+ and ALDH- cell population. 
Figure 6: Effects of risk-TF knock-down on cell proliferation. 
Growth curves for (a) ER- cell line MCF10A and (b) the ER+ cell line ZR751 after 
transient transfection of the siRNAs as indicated. Cells transfected with a scrambled 
siRNA were included as a control. Error bars depict the standard error of the mean of 
8 wells each in a minimum of two independent experiments (methods). The statistical 
analysis (insets) compares the growth curves using 100,000 simulations, with p-
values adjusted by the BY correction method. 
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Figure 7: The ESR1 regulon as read-out of cell state.  
(a and b) Examples of two tumours for which 2-tailed GSEA was carried out. The 
ESR1 regulon is split into targets activated by ESR1 (red bars) and targets repressed 
by ESR1 (blue bars). GSEA is carried out for each group. The running enrichment 
scores are shown. The differential enrichment scores (dES) are obtained by 
subtracting the maximal deviation from zero for the running enrichment score for 
repressed targets from that obtained for activated targets. (c) dES calculated for all 
tumours in METABRIC cohort I. Black bars indicate the ER status, PAM50 subclass 
and tumour grade for each of the tumours analysed. (d) Kaplan-Meier survival curve 
for disease-specific survival for each of the tumour subgroups highlighted in c. The 
number of patients in each section is listed, with the number of patients who died in 
brackets. (e and f) Kaplan-Meier survival curves for immunohistochemically ER+ 
tumours in cohort I and II, respectively, of the METABRIC patients comparing those 
in which the ESR1 regulon is in an activated state (dES>0 and ESA>0 and ESB<0) to 
those with repressed ESR1 regulons (dES<0 and ESA<0 and ESB>0). (g and h) 2-
tailed GSEA in MCF-7 cells activated by estrogen (E2) or estrogen plus tamoxifen. 
Phenotypes were defined as differential gene expression between estrogen and vehicle 
treated cells (g) or between estrogen plus tamoxifen and estrogen (h) treatment.  
 
Figure 8:  
Schematic model of mammary gland cell populations. In this model we show the 
predominant expression of cluster 1 versus cluster 2 risk-TFs with respect to the cell 
populations found in the mammary gland and the cancer subtypes that arise from 
them. In the normal mammary gland all three populations have self-renewal capacity. 
Claudinlow tumours were originally classified as basal in the PAM signature, but are 
likely to represent a separate lineage arising from myoepithelial cells40. Basal-like 
cancer is thought to arise from alveolar progenitor cells, (The somewhat misleading 
term ‘basal-like’ reflects the fact these tumours not only express epithelial, but also 
mesenchymal cell surface markers that are also highly expressed in the myoepithelial 
lineage located near the basal membrane.) and luminal A/B cancer from ER+ 
precursors.  
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Online Methods 
 
Computational Analysis 
ARACNe/EVSE analysis 
Regulons were calculated based on mutual information using the ARACNe 
algorithm3. Of the 809 TFs3 tested, we were able to assign regulons to 555 TFs in 
cohort I and 635 in cohort II of the METABRIC data set. The EVSE analysis has been 
described before4 and here we extended our previous computational pipeline (RTN16) 
to allow the testing of all regulons defined in the network. Supplementary Figure 2 
illustrates the steps and data sets used in this analysis. In more detail, EVSE was 
carried out using the 72 breast cancer risk SNPs identified by Michailidou et al.5. For 
most of these GWAS loci neither the causative SNP nor the potential target genes are 
known. To deal with the former, the top hit at each locus (tagging SNP) was expanded 
into an AVS including all SNPs with a D'> 0.99 and a LOD>3.0 (Supplementary Fig. 
2a), following the previously published VSE method7. This approach gave similar 
results to those obtained using r2 to expand the tagging SNP into the AVS 
(Supplementary Fig. 8). To identify potential target genes at each GWAS locus, we 
used gene expression and genotyping data in a multivariate eQTL analysis4. When 
considering multiple GWAS loci in a single analysis, the number of potential target 
genes may vary strongly for each GWAS locus to be analysed, making statistical 
comparisons between them difficult. For this reason we carried out a single 
multivariate eQTL analysis at each GWAS locus, asking whether there is an 
association of any of the SNPs in the AVS and the expression of any of the genes in a 
given regulon in a window of +/- 250kb around the AVS (Supplementary Fig 2b,c). 
(For each AVS only those SNPs for which genotyping data was available in 
METABRIC were considered in the analysis.) If a positive association was found, the 
locus was counted towards a mapping tally (Supplementary Fig. 2d) as described by 
Cowper Sal Iari et al7. In a subsequent step statistical significance was assessed 
(Supplementary Fig. 2e). To reduce the cost of the computational analysis when 
interrogating many regulons, we ran a low resolution analysis to remove obviously 
non-significant regulons (RTN package16). For all remaining regulons the EVSE 
analysis using breast cancer GWAS hits was tested against a null distribution based 
on random permutations of the AVS (that is, matched random variant sets). These 
distributions were normalised and centred around the null to obtain the enrichment 
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score, which is the number of standard deviations that the observed mapping tally 
deviates from the null mapping mean. From these null distributions p-values were 
calculated. To gain confidence in our results we used cohort I and II of the 
METABRIC data set separately and only considered regulons that were significant in 
both cohorts. Where different GWAS results were tested (BMD, prostate cancer and 
CLL), each GWAS set was controlled with the appropriate number of random SNPs. 
As threshold for significance a Bonferroni correction was applied.  
 
eQTL analysis 
We performed a cis-eQTL analysis for cohort I and cohort II breast cancer samples 
generated by the METABRIC study6. The analysis largely followed that by Li et al10. 
We required probes to map to one of the RefSeq genes according to the annotation 
data obtained from the R package illuminaHumanv3.db45. Probes that map to genes in 
the highly polymorphic human leukocyte antigen region were excluded from the 
analysis. Genes with low expression levels (within 10% quantile of all expression 
values) were removed. Probes mapping to the same gene were treated independently 
in the eQTL analysis. 
 
Copy number values for each gene of each sample were estimated from the 
segmented copy numbers by averaging the copy number of all segments that fall into 
the region of the gene while using the length of the copy number segments as weights. 
Gene expression levels were adjusted for copy number effects, using the equation 
Ti = βi CNi + εi , 
where, Ti is the measured gene expression, CNi is the copy number value, βi is the 
regression coefficient and εi is the residual gene expression level of gene i. 
 
The eQTL analysis was performed using MatrixEQTL in R46 by correlating the 
genotypes of all remaining SNPs with the residual expression levels of proximal 
genes, i.e. genes within 1 Mb of the SNP. In the case that multiple probes map to a 
gene, all probes of that gene were tested separately. Finally, significant associations 
were selected based on a Benjamini-Hochberg False Discovery Rate (FDR) threshold 
of 0.1. Only SNPs with minor allele frequency (MAF) greater than 0.05 were tested. 
This is necessary because the effect of different genotypes on transcript levels cannot 
be evaluated if the genotypes at a given SNP locus are very homogeneous.  
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MRA analysis 
The master regulator analysis uses a hypergeometric test to assess whether a gene list 
is enriched in a given regulon15. If significant the TF controlling the regulon is likely 
to be involved in the regulation of the gene list. Our experimental design compares 
resting with cycling cells and we therefore removed TFs that were also enriched with 
the Meta-PCNA signature47 (Supplementary Note).  
 
VSE analysis 
The variant set enrichment analysis was carried out as previously described7 using 
publically available data4,13,23 (GSE48930, GSE41995, E-MTAB-223, GSM1010889, 
E-MTAB-986). Briefly, VSE analysis tests enrichment of a chromosomal annotation, 
here TF-binding sites, at the AVSs. An overlap between a ChIP-seq peak and a SNP 
in the AVS is counted towards a mapping tally that is tested against random SNPs as 
in the EVSE.   
 
Differential gene expression 
Differential gene expression was assessed using limma48. Z-scores were obtained by 
comparing the gene expression values averaged across all cell populations in the 
analysis against averages of subgroups tested in each case. When determining 
significant differences in gene expression across primary cell populations, the 
following contrasts were examined: ALDH+ versus ALDH- cells, ALDH+ versus 
EpCAM+ CD49f- cells and ALDH- versus EpCAM+ CD49f- cells.  
 
Two-tailed gene set enrichment analysis (GSEA) 
GSEA49 assesses the skewed distribution of a selected gene set (S), here the ESR1 
regulon, in a list of genes (L) ranked by a particular phenotype, in this case the 
differential gene expression observed when comparing a given tumour with the 
average expression for all METABRIC tumours. The enrichment score (ES) was 
calculated by walking down the list L, increasing by 1/|S| a running-sum statistic 
when encountering a gene in S and decreasing it by 1/(|L|-|S|) when encountering a 
gene not in S. The ES is the maximum deviation from zero. The two-tailed GSEA 
method is based on the Connectivity Map (CMAP) procedure50. The ESR1 regulon 
was derived by ARACNe from METABRIC cohort I and filtered using genefilter in 
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Bioconductor51 to remove uninformative genes, about 15% of the regulon mostly of 
low variance. Feature selection is performed on cohort II and used to filter the regulon 
in cohort I and vice versa. The resultant regulon was split into two subgroups, positive 
targets (A) and negative targets (B) using Pearson’s correlation to assign 
directionality. The distribution of A and B was then tested by the GSEA statistics in 
the ranked phenotype, producing independent enrichment scores for each subgroup. 
An additional step calculated the differential enrichment (dES=ESA-ESB). The two-
tailed GSEA was performed in R using the function tni.gsea2 in the RTN package4,16 
with 1000 permutations.  
 
Survival data6 were used to plot Kaplan-Meier curves and p-values were calculated 
using the log-rank statistics. On the basis of dES values the patients fell into three 
groups: those with an active ESR1 regulon (dES>0 and ESA>0 and ESB<0), those with 
a repressed ESR1 regulon (dES<0 and ESA<0 and ESB>0) and a small group in which 
the dES values were around zero (inconclusive, with ESA and ESB distributions 
skewed to the same side). The two large groups were further subdivided in half.  
 
We tested the response of the ESR1 regulon to estrogen or estrogen plus tamoxifen 
treatment by applying the two-tailed GSEA to gene expression data from Hurtado et 
al.23 using the differential gene expression (estrogen versus vehicle and estrogen 
versus estrogen plus tamoxifen, GSE25316) as the phenotype to rank the gene list (L). 
 
Cell culture 
The human breast cancer cells MCF-7 and MDA-MB-453 (HTB 131; ATCC, USA) 
were cultured in DMEM (Invitrogen), ZR751 and T47D were cultured in RPMI 
(Invitrogen), all supplemented with 10% FBS and antibiotics, and MCF10A in 
DMEM, 5% horse serum, 5ug/mL insulin, 1 ug/mL hydrocortisone, 100 ng/mL 
cholera toxin, 20 ng/mL EGF and L-glutamine. Unless otherwise stated all cells were 
from the CRUK Cambridge Institute biorepository and maintained at 37°C, 5% CO2.  
 
Chromatin immunoprecipitation (ChIP) 
ChIP-seq experiments were carried out as previously described52. Cells were seeded 
at ~70% confluence into 15-cm tissue culture dishes (4 per treatment). Following 
overnight attachment, cells were starved using base media containing 5% steroid-
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stripped FBS. To ensure steroid depletion prior to treatment, media was changed 
every day for 3 days; then cells were treated for 4 hours with vehicle control 
(ethanol), 5α-dihydrotestosterone (DHT; 10nM), medroxyprogesterone acetate (MPA; 
10nM). Cells were cross-linked and ChIP-seq performed using an AR antibody (N20; 
sc-816; Santa Cruz Biotech; 10 µg/IP) with subsequent data processing as previously 
described28. Two independent experiments were performed in each cell line and 
consensus AR chromatin binding events determined for each treatment condition.  
 
Gene expression analysis after estrogen and FGF10 signalling 
MCF-7 cells were plated at 5x105 cells/well in 6-well dishes and left in complete 
medium overnight. Cell synchronisation via estrogen-starvation was then carried out 
for three days in estrogen-free media (phenol red-free media supplemented with 5% 
charcoal dextran-treated FBS and 2 mM L-glutamine), with media changed every 24 
hours. Estrogen-deprived cells were stimulated with 1 nM β-estradiol (E2; Sigma) or 
100 ng/ml FGF10 (Invitrogen) in combination with 1 nM E2. 6 hours after cell 
treatment, total RNA was isolated from 3 biological replicates, quality controlled and 
used for cRNA amplification and labeling using the Illumina TotalPrep-96 kit 
(Ambion). cRNA was hybridised to HumanHT-12 v4 Expression BeadChips 
according to the manufacturer’s protocol (Illumina WGGX DirectHyb Assay Guide 
11286331 RevA). Raw image files were processed and analysed using the beadarray 
package from Bioconductor. 
 
Transient transfection of siRNA 
Cell lines were transfected with ON-TARGETplus SMARTpool siRNA (Dharmacon) 
directed against risk-TFs NFIB (L-008456-00), YBX1 (L-010213-00), CBFB (L-
011602-00), LMO4 (L-012124-00), ELF5 (L-011265-02), TBX19 (L-011910-00) and 
SOX10 (L-017192-00). CEBPB was not included in the analysis as multiple distinct 
isoforms with opposing function may be present in the cell. A custom siRNA was 
used against FOXA123. Knock-down of mRNA was confirmed for each cell line by 
RT-PCR of cDNA 48 hours after transfection (Supplementary Fig. 20c) using the 
primer pairs shown in Supplementary Table 5. 1 μg of total RNA was reverse 
transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) and qRT-PCR performed using cDNA obtained from 10 ng of total 
 26
RNA. qRT-PCR was performed using an ABI 9800HT Sequence Detection System 
(Applied Biosystems) with SDS software version 2.3. Amplification and detection 
were carried out in 384-well Optical Reaction Plates (Applied Biosystems) with 
Power SYBR Green Fast 2x qRT-PCR Mastermix (Applied Biosystems). All 
expression data were normalised to DGUOK expression. Primer-specificity was 
confirmed at the end of each qRT-PCR run through the generation of single peaks in 
melt-curve analysis. siRNA against SOX10 did not cause a reduction in mRNA levels 
and was not examined further. A control non-targeting pool of siRNAs (D-001810-
01-05) was included in each experiment. Transfections were carried out using 
Lipofectamine RNAiMax Reagent (Invitrogen), according to manufacturer’s protocol. 
Growth was measured in 96-well plates using the IncuCyte (Essen BioScience) 
system every 3 hours. 8 wells were averaged for each experiment and at least two 
repeats were carried out for each cell line (MCF10A n=3, ZR751 n=2). The results of 
knock-downs for TFs in cluster 2 that are not consensus risk-TFs are shown in 
Supplementary Fig. 20). Statistical analysis was carried out using the 
compareGrowthCurves command in the statmod package53 in R, generating BY54 
adjusted p-values.  
 
Source code 
The source code developed in this study is publicly available from the Bioconductor55 
in the R packages RTN4 and RedeR56. 
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